Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.49 |
| ▸ | F9 | P00740 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 6/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851174 | 0.85 | KMT2A (0.51) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL5851156 | 0.83 | HTR1B (0.44) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL8801424 | 0.79 | HTR1B (0.50) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL8723087 | 0.79 | HTR1A (0.55) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL3794323 | 0.78 | HTR1B (0.55) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL29966872 | 0.77 | TUBB4A (0.42) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL3374948 | 0.76 | HTR1A (0.46) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL3385465 | 0.76 | RHEB (0.45) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL502401 | 0.75 | HTR1B (0.52) | HTR1BHTR1AADRB3CYP1A2CYP3A4 | |
| SCHEMBL7084585 | 0.75 | HTR1B (0.52) | HTR1BHTR1AADRB3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951315-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | Ilypsa, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-7098234-B2 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| CN-1179945-C | Indole derivatives, process for preparation of same and use thereof | СҰҩƷ��ҵ��ʽ���� | 2004-12-15 | — | — | CN | disclosed |
| US-20040180885-A1 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICAL CO., LTD. | 2004-09-16 | — | — | US | disclosed |
| US-6743793-B2 | DP RECEPTOR ANTAGONIST; PROSTAGLANDIN D | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030176400-A1 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| CN-1427824-A | Indole derivatives, process for preparation of same and use thereof | ONO PHARMACEUTICAL CO (JP) | 2003-07-02 | — | — | CN | disclosed |
| EP-1262475-A1 | INDOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176400-A1 | Indole derivatives, process for preparation of the same and use thereof | IDO1, KIT, ITCH | HTR1B 65/4885F9 4095/4885PLAU 969/4885 |
| US-20040180885-A1 | Indole derivatives, process for preparation of the same and use thereof | IDO1, KIT, ITCH | HTR1B 65/4885F9 4095/4885PLAU 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.